THE FIRST AND ONLY HRIG STUDIED IN PEDIATRIC PATIENTS1

Learn more about KEDRAB (Rabies Immune Globulin [Human]) – the only FDA-approved human rabies immune globulin (HRIG) studied in children.1

 

Kedrion Biopharma is committed to rabies education, prevention, and clinical excellence and maintains valuable relationships within the rabies prevention community.

The KEDRAB Brochure

Please complete the form below to receive your information.

Required *






Terms and Conditions: Kedrion Biopharma Inc. (“Kedrion Biopharma”) respects the privacy of your personal information. Kedrion Biopharma, and companies providing services to Kedrion Biopharma, may use the information that you provide to send you marketing or informational materials, analyze and use your information to improve or develop services and programs, and contact you about marketing programs or research about health topics that may be of interest to you.

Kedrion Biopharma, and companies providing services to Kedrion Biopharma, will not sell or rent your personally identifiable information. For more information regarding our Privacy Policy, click here.

Reference: 1. KEDRAB [package insert]. Fort Lee, NJ: Kedrion Biopharma Inc.; 2021.

Array

SAME KEDRAB, IMPROVED PRODUCT PACKAGING

  • Enhanced color packaging for clear identification of 2mL and 10mL dosage options
  • User-friendly vertical barcodes on vials for easier scanning

New KEDRAB packaging, with distinctive vial sizes and colors, designed to reduce chances of error

Over the next several months, you can expect to start receiving KEDRAB® (Rabies Immune Globulin [Human]) with enhanced product packaging, as pictured above. Products with new packaging will be shipped when available, and after distributors' current supplies become depleted. As such, it is likely you may not receive both the new 2mL and 10mL product packaging at the same time.